Traumatic Brain Injury

Neurology·MeSH: Stress Disorders, Post-Traumatic

Prevalence

30.0 / 100K

23 drugs in development·13 companies·29 clinical trials

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
NT 201	Revance Therapeutics, Inc. (RVNC)
Standard Care	UNITED THERAPEUTICS Corp (UTHR)

Phase 2(10)

Drug	Company
allopregnanolone	GH Research PLC (GHRS)
BoNT A	UNITED THERAPEUTICS Corp (UTHR)
BoNT A	Revance Therapeutics, Inc. (RVNC)
Cold Stored Platelets	UNITED THERAPEUTICS Corp (UTHR)
muse stem cell therapy	HWH International Inc. (HWH)
onp-002	ORAGENICS INC (OGEN)
oxycyte	TENAX THERAPEUTICS, INC. (TENX)
Sham	Valneva SE (VALN)
Tranexamic Acid	UNITED THERAPEUTICS Corp (UTHR)
Valproic Acid	UNITED THERAPEUTICS Corp (UTHR)

Phase 1(2)

Drug	Company
Angiotensin	UNITED THERAPEUTICS Corp (UTHR)
Zoledronic acid	UNITED THERAPEUTICS Corp (UTHR)

Preclinical(8)

Drug	Company
ALPHA-1062 intranasal (ALPHA-1062IN)	Alpha Cognition Inc. (ACOG)
alpha-1062 sublingual	Alpha Cognition Inc. (ACOG)
ANVS405	Annovis Bio, Inc. (ANVS)
feldetrex	PREMIER BIOMEDICAL INC (BIEI)
ht-tbi	Hoth Therapeutics, Inc. (HOTH)
kls-13019	NEUROPATHIX, INC. (TYGS)
kls-13023	NEUROPATHIX, INC. (TYGS)
sequential-dialysis technique	PREMIER BIOMEDICAL INC (BIEI)

Phase 4(1)

Drug	Company
Sufentanyl	COGNITION THERAPEUTICS INC (CGTX)

BioSniper tracks 23 drugs in development for Traumatic Brain Injury across 13 companies.

There are 29 clinical trials targeting Traumatic Brain Injury tracked by BioSniper.

The estimated prevalence of Traumatic Brain Injury is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.